The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S17-S25 , December 2006

The Confounding Issue of Comorbid Renal Insufficiency

  • Gregg C. Fonarow, MD

      Affiliations

    • Division of Cardiology, David Geffen School of Medicine at UCLA, University of California–Los Angeles, Los Angeles, California, USA
    • Corresponding Author InformationRequests for reprints should be addressed to Gregg C. Fonarow, MD, Division of Cardiology, David Geffen School of Medicine at UCLA, University of California–Los Angeles, 10833 Le Conte Avenue, Los Angeles, California 90095.
    • ,
  • J. Thomas Heywood, MD

      Affiliations

    • Scripps Clinic, La Jolla, California, USA

References 

  1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). [published correction appears in J Am Coll Card. 2006;47:1503–1505] J Am Coll Cardiol. 2005;46:e1–e82
  2. Nieminen MS, Böhm M, Cowie MR, et al. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:384–416
  3. Swedberg K, Cleland J, Dargie H, et al. Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology (Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005)). Eur Heart J. 2005;26:1115–1140
  4. NHLBI Working Group. Cardio-renal connections in heart failure and cardiovascular disease: executive summary. 2006;Available at: http://www.nhlbi.nih.gov/meetings/workshops/cardiorenal-hf-hd.htm. Accessed June 20.
  5. Bongartz LG, Cramer MJ, Doevendans PA, Joles JA, Braam B. The severe cardiorenal syndrome: Guyton revisited. Eur Heart J. 2005;26:11–17
  6. Heywood JT. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195–201
  7. Boerrigter G, Burnett JC. Cardiorenal syndrome in decompensated heart failure: prognostic and therapeutic implications. Curr Heart Fail Rep. 2004;1:113–120
  8. Krumholz HM, Chen YT, Vaccarino V, et al. Correlates and impact on outcomes of worsening renal function in patients ≥65 years of age with heart failure. Am J Cardiol. 2000;85:1110–1113
  9. Cleland JGF, Swedberg K, Follath F, et al. The EuroHeart Failure survey programme—a survey on the quality of care among patients with heart failure in Europe (Part 1: patient characteristics and diagnosis). Eur Heart J. 2003;24:442–463
  10. Adams KF, Fonarow GC, Emerman CL, et al. ADHERE Scientific Advisory Committee and Investigators Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J. 2005;149:209–216
  11. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–147
  12. Heywood JT, Fonarow GC, Wynne J. Is heart failure really renal failure? (Observations from 88,075 admissions with decompensated heart failure in the ADHERE Registry). J Am Coll Cardiol. 2005;45(suppl A):173A;Abstract 843-8
  13. Smith GL, Vaccarino V, Kosiborod M, et al. Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure?. J Card Fail. 2003;9:13–25
  14. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136–141
  15. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61–67
  16. Hillege HL, Girbes ARJ, de Kam PJ, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation. 2000;102:203–210
  17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41
  18. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:681–689
  19. Hill JA, Shah MR, Hasselblad V, et al. Pulmonary artery catheter use does not change the contribution of renal dysfunction to outcomes in patients with advanced heart failure: findings from ESCAPE. Circulation. 2004;110(suppl 3):III-638;Abstract 2964
  20. Fonarow GC, Adams KF, Abraham WT, Yancy CW, Boscardin WJ ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572–580
  21. Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med. 2004;116:466–473
  22. Felker GM, Gattis WA, Leimberger JD, et al. Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol. 2003;92:625–628
  23. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA. 2003;290:2581–2587
  24. Krumholz HM, Chen Y-T, Wang Y, Vaccarino V, Radford MJ, Horwitz RI. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J. 2000;139:72–77
  25. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689–1694
  26. McCullough PA, Kuncheria J, Mathur VS. Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. Rev Cardiovasc Med. 2004;5:16–25
  27. Gray BH, Olin JW, Childs MB, Sullivan TM, Bacharach JM. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med. 2002;7:275–279
  28. Collins AJ. Cardiovascular mortality in end-stage renal disease. Am J Med Sci. 2003;325:163–167
  29. Cotter G, Moshkovitz Y, Milovanov O, et al. Acute heart failure: a novel approach to its pathogenesis and treatment. Eur J Heart Fail. 2002;4:227–234
  30. Brewster UC, Setaro JF, Perazella MA. The renin-angiotensin-aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci. 2003;326:15–24
  31. Fonarow GC. Pharmacologic therapies for acutely decompensated heart failure. Rev Cardiovasc Med. 2002;3(suppl 4):S18–S27
  32. Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA. 2002;287:1531–1540
  33. Epstein BJ. Elevations in serum creatinine concentration: concerning or reassuring?. Pharmacotherapy. 2004;24:697–702
  34. Juhlin T, Björkman S, Gunnarsson B, Fyge Å, Roth B, Höglund P. Acute administration of diclofenac, but possibly not long term low dose aspirin, causes detrimental renal effects in heart failure patients treated with ACE-inhibitors. Eur J Heart Fail. 2004;6:909–916
  35. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104:1985–1991
  36. Sanchez V, Delgado JF, Morales JM, et al. Chronic cyclosporine-induced nephrotoxicity in heart transplant patients: long-term benefits of treatment with mycophenolate mofetil and low-dose cyclosporine. Transplant Proc. 2004;36:2823–2825
  37. Silverberg D, Wexler D, Blum M, Schwartz D, Iaina A. The association between congestive heart failure and chronic renal disease. Curr Opin Nephrol Hypertens. 2004;13:163–170
  38. Yoshida H, Yashiro M, Liang P, et al. Mesangiolytic glomerulopathy in severe congestive heart failure. Kidney Int. 1998;53:880–891
  39. Joles JA, Koomans HA. Causes and consequences of increased sympathetic activity in renal disease. Hypertension. 2004;43:699–706
  40. Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema?. Lancet. 1988;1:1033–1035
  41. Ichikawa I, Pfeffer JM, Pfeffer MA, Hostetter TH, Brenner BM. Role of angiotensin II in the altered renal function of congestive heart failure. Circ Res. 1984;55:669–675
  42. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure (Relationship of cardiac index to kidney function). Drugs. 1990;39(suppl 4):10–21
  43. Packer M. Why do the kidneys release renin in patients with congestive heart failure? (A nephrocentric view of converting-enzyme inhibition). Am J Cardiol. 1987;60:179–184
  44. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283–1289
  45. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med. 2000;160:685–693
  46. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD Collaborative Study Group. The effect of angiotensin-converting–enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456–1462
  47. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(suppl 1):S1–S290
  48. Ljungman S, Kjekshus J, Swedberg K CONSENSUS Trial Group. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70:479–487
  49. Akhter MW, Aronson D, Bitar F, et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol. 2004;94:957–960
  50. Bongartz LG, Cramer MJ, Braam B. The cardiorenal connection [letter]. Hypertension. 2004;43:e14
  51. Boerrigter G, Burnett JC. Recent advances in natriuretic peptides in congestive heart failure. Expert Opin Investig Drugs. 2004;13:643–652
  52. Yeyati NL, Adrogué HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol. 1996;16:471–477
  53. Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105:1348–1353
  54. Ikram H, Chan W, Espiner EA, Nicholls MG. Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci. 1980;59:443–449
  55. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? (Part I: inotropic infusions during hospitalization). Circulation. 2003;108:367–372
  56. Chatterjee K, Parmley WW, Cohn JN, et al. A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. Am Heart J. 1985;110:439–447
  57. Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44:595–601
  58. Caps MT, Perissinotto C, Zierler RE, et al. Prospective study of atherosclerotic disease progression in the renal artery. Circulation. 1998;98:2866–2872
  59. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis. 2000;35:S97–S105
  60. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P. Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol. 2001;38:963–968
  61. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology. 2001;96:132–143
  62. Neuberg GW, Miller AB, O’Connor CM, et al. PRAISE Investigators Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31–38
  63. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–395
  64. Cotter G, Weissgarten J, Metzkor E, et al. Increased toxicity of high-dose furosemide versus low-dose dopamine in the treatment of refractory congestive heart failure. Clin Pharmacol Ther. 1997;62:187–193
  65. Palmer BF. Impaired renal autoregulation: implications for the genesis of hypertension and hypertension-induced renal injury. Am J Med Sci. 2001;321:388–400
  66. Heywood JT. Combining nesiritide with high-dose diuretics may increase the risk of increased serum creatinine. J Card Fail. 2005;11(suppl):S154;Abstract 950473
  67. Mehta RL, Pascual MT, Soroko S, Chertow GM PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA. 2002;288:2547–2553
  68. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure: activation of the neurohumoral axis. Ann Intern Med. 1985;103:1–6
  69. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724–1729
  70. Kubo SH, Clark M, Laragh JH, Borer JS, Cody RJ. Identification of normal neurohormonal activity in mild congestive heart failure and stimulating effect of upright posture and diuretics. Am J Cardiol. 1987;60:1322–1328
  71. Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705–708
  72. Dormans TPJ, van Meyel JJM, Gerlag PGG, Tan Y, Russel FGM, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 1996;28:376–382
  73. Kramer WG, Smith WB, Ferguson J, et al. Pharmacodynamics of torsemide administered as an intravenous injection and as a continuous infusion to patients with congestive heart failure. J Clin Pharmacol. 1996;36:265–270
  74. Lahav M, Regev A, Ra’anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992;102:725–731
  75. McBride BF, White CM. Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management. Pharmacotherapy. 2003;23:997–1020
  76. Pivac N, Rumboldt Z, Sardelic S, et al. Diuretic effects of furosemide infusion versus bolus injection in congestive heart failure. Int J Clin Pharmacol Res. 1998;18:121–128
  77. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;1:CD003178
  78. Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med. 1997;25:1969–1975
  79. van Meyel JJ, Smits P, Dormans T, Gerlag PG, Russel FG, Gribnau FW. Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med. 1994;235:329–334
  80. Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191–199
  81. Agostoni PG, Marenzi GC, Pepi M, et al. Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol. 1993;21:424–431
  82. Kiyingi A, Field MJ, Pawsey CC, Yiannikas J, Lawrence JR, Arter WJ. Metolazone in treatment of severe refractory congestive cardiac failure. Lancet. 1990;335:29–31
  83. Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol. 1999;19:581–597
  84. DiDomenico RJ, Park HY, Southworth MR, et al. Guidelines for acute decompensated heart failure treatment. Ann Pharmacother. 2004;38:649–660
  85. Abraham WT, Adams KF, Fonarow GC, et al. ADHERE Scientific Advisory Committee and Investigators and the ADHERE Study Group In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol. 2005;46:57–64
  86. Arnold LM, Carroll NV, Oinonen M, Crouch MA. Mortality and length of hospital stay in patients receiving dobutamine, milrinone, or nesiritide for acute decompensated heart failure. J Card Fail. 2004;10(suppl 4):S103;Abstract 317
  87. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial. Circulation. 2004;110(suppl 3):III-515;Abstract 2415
  88. Ewy GA. Inotropic infusions for chronic congestive heart failure: medical miracles or misguided medicinals?. J Am Coll Cardiol. 1999;33:572–575
  89. Nieminen MS, Akkila J, Hasenfuss G, et al. Study Group Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000;36:1903–1912
  90. Aronson D, Horton DP, Burger AJ. The effect of dobutamine on neurohormonal and cytokine profiles in patients with decompensated congestive heart failure. J Card Fail. 2001;7(suppl 2):28;Abstract 095
  91. de Vivo F, DeSanto LS, Maiello C, et al. Role of the heart surgeon in the emergency treatment of diuretic resistant edema in grades III-IV heart failure. Kidney Int Suppl. 1997;59:S66–S68
  92. Ferreira A, Bettencourt P, Dias P, et al. Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci. 2001;100:557–566
  93. Packer M, Lee WH, Kessler PD, Gottlieb SS, Medina N, Yushak M. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med. 1987;317:799–804
  94. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail. 1998;4:37–44
  95. Aronson D, Burger AJ. Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure. Am J Cardiol. 2002;90:435–438
  96. Colucci WS, Elkayam U, Horton DP, et al. Nesiritide Study Group Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343:246–253
  97. Jensen KT, Eiskjaer H, Carstens J, Pedersen EB. Renal effects of brain natriuretic peptide in patients with congestive heart failure. Clin Sci (Lond). 1999;96:5–15
  98. Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure: a double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94:3184–3189
  99. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation. 2005;111:1487–1491
  100. Elkayam U, Singh H, Akhter MW, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. J Card Fail. 2004;10(suppl 4):S88;Abstract 256
  101. Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110:1620–1625
  102. Abraham WT. Serum creatinine elevations in patients receiving nesiritide are related to starting dose. J Card Fail. 2005;11(suppl):S156;Abstract 248
  103. Elkayam U. Nesiritide may diminish the increased acute mortality risk associated with worsening renal function. Circulation. 2005;112(suppl II):676;Abstract 3168

PII: S0002-9343(06)01143-0

doi: 10.1016/j.amjmed.2006.09.013

The American Journal of Medicine
Volume 119, Issue 12, Supplement 1 , Pages S17-S25 , December 2006

Article Tools

* Image Usage & Resolution